• Leukemias, lymphomas, and other hematologic cancers

Elzonris Generic Name & Formulations

General Description

Tagraxofusp-erzs 1000mcg/mL; soln for IV infusion after dilution; preservative-free.

Pharmacological Class

CD123-directed cytotoxin.

How Supplied

Single-dose vial (1mL)—1

Generic Availability


Elzonris Indications


Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Elzonris Dosage and Administration

Adults and Children

<2yrs: not established. Premedicate with an H1-histamine antagonist, H2-histamine antagonist, corticosteroid, and APAP ~60mins prior to each dose. ≥2yrs: 12mcg/kg via IV infusion over 15mins once daily on Days 1–5 of a 21-day cycle until disease progression or unacceptable toxicity. May extend dosing period for dose delays up to Day 10 of the cycle. Observation following each infusion, dose modifications, and CLS management: see full labeling.

Elzonris Contraindications

Not Applicable

Elzonris Boxed Warnings

Boxed Warning

Capillary leak syndrome (CLS).

Elzonris Warnings/Precautions


Risk of capillary leak syndrome (may be fatal); monitor for signs/symptoms. Ensure adequate cardiac function and serum albumin ≥3.2g/dL prior to initiation. Monitor serum albumin levels prior to each dose during therapy and clinically thereafter. Monitor for hypersensitivity reactions; interrupt and treat as needed if occurs. Monitor ALT/AST prior to each infusion; withhold if transaminases >5×ULN; resume when resolved. Elderly. Pregnancy: exclude status within 7 days prior to initiation. Advise females of reproductive potential to use effective contraception during and for ≥1 week after last dose. Nursing mothers: not recommended (during and for 1 week after last dose).

Elzonris Pharmacokinetics

See Literature

Elzonris Interactions

Elzonris Adverse Reactions

Adverse Reactions

CLS, nausea, fatigue, peripheral edema, pyrexia, weight increase, lab abnormalities; hypersensitivity, hepatotoxicity.

Elzonris Clinical Trials

See Literature

Elzonris Note

Not Applicable

Elzonris Patient Counseling

See Literature